The content on this site is intended for healthcare professionals only
Dr Ashley Yocum speaks to ecancer about the Beat AML master trial.
The goal of this study is to develop better individualised treatments for patients diagnosed with AML.
The study is a precision medicine master study that assigns newly diagnosed or relapsed or refractory patients with AML to a biomarker-specific treatment within seven days based on targeted genomic sequencing in cytogenetics.
Dr Yocum says that the trial showed that patients had favourable outcomes if they received intensive chemotherapy over the other two treatment options in the study.
She also discusses some of the sub-studies from this trial presented at ASH 2023.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
Encouraging results using mismatched unrelated donors in stem cell transplantation
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma
Multiple myeloma in a resource constrained setting
